JP7155276B2 - フェニルピロリジノンホルミルペプチド２受容体アゴニスト - Google Patents

フェニルピロリジノンホルミルペプチド２受容体アゴニスト Download PDF

Info

Publication number
JP7155276B2
JP7155276B2 JP2020546499A JP2020546499A JP7155276B2 JP 7155276 B2 JP7155276 B2 JP 7155276B2 JP 2020546499 A JP2020546499 A JP 2020546499A JP 2020546499 A JP2020546499 A JP 2020546499A JP 7155276 B2 JP7155276 B2 JP 7155276B2
Authority
JP
Japan
Prior art keywords
alkyl
halo
hydrogen
alkoxy
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020546499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516240A (ja
JP2021516240A5 (enExample
Inventor
プラビン・スダカール・シルデ
ビシュウェシュワライアー・バリガル
バラジ・セシャドリ
アミット・クマール・チャットパディヤイ
ニコラス・アール・ワーツ
エレン・ケイ・キック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2021516240A publication Critical patent/JP2021516240A/ja
Publication of JP2021516240A5 publication Critical patent/JP2021516240A5/ja
Application granted granted Critical
Publication of JP7155276B2 publication Critical patent/JP7155276B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/304—Aromatic acids (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020546499A 2018-03-05 2019-03-04 フェニルピロリジノンホルミルペプチド２受容体アゴニスト Active JP7155276B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862638556P 2018-03-05 2018-03-05
US62/638,556 2018-03-05
PCT/US2019/020493 WO2019173182A1 (en) 2018-03-05 2019-03-04 Phenylpyrrolidinone formyl peptide 2 receptor agonists

Publications (3)

Publication Number Publication Date
JP2021516240A JP2021516240A (ja) 2021-07-01
JP2021516240A5 JP2021516240A5 (enExample) 2021-08-12
JP7155276B2 true JP7155276B2 (ja) 2022-10-18

Family

ID=65812419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020546499A Active JP7155276B2 (ja) 2018-03-05 2019-03-04 フェニルピロリジノンホルミルペプチド２受容体アゴニスト

Country Status (30)

Country Link
US (3) US10676431B2 (enExample)
EP (2) EP3762380B1 (enExample)
JP (1) JP7155276B2 (enExample)
KR (1) KR102803660B1 (enExample)
CN (1) CN111868052B (enExample)
AR (1) AR114429A1 (enExample)
AU (1) AU2019232704B2 (enExample)
BR (1) BR112020017744A2 (enExample)
CA (1) CA3092927A1 (enExample)
CL (1) CL2020002224A1 (enExample)
CY (1) CY1124985T1 (enExample)
DK (1) DK3762380T3 (enExample)
EA (1) EA202092094A1 (enExample)
ES (2) ES3061495T3 (enExample)
HR (1) HRP20220118T1 (enExample)
HU (1) HUE058044T2 (enExample)
IL (1) IL277044B2 (enExample)
LT (1) LT3762380T (enExample)
MX (1) MX2020009000A (enExample)
MY (1) MY204384A (enExample)
PE (1) PE20210046A1 (enExample)
PL (1) PL3762380T3 (enExample)
PT (1) PT3762380T (enExample)
RS (1) RS62833B1 (enExample)
SG (1) SG11202008504SA (enExample)
SI (1) SI3762380T1 (enExample)
SM (1) SMT202200067T1 (enExample)
TW (1) TWI804585B (enExample)
WO (1) WO2019173182A1 (enExample)
ZA (1) ZA202006115B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180081528A (ko) * 2015-11-24 2018-07-16 브리스톨-마이어스 스큅 컴퍼니 심장 질환의 치료를 위한 포르밀-펩타이드 수용체 2/리폭신 a4 수용체 (fpr2/alx) 타겟팅
JP7094989B2 (ja) 2017-06-09 2022-07-04 ブリストル－マイヤーズ スクイブ カンパニー シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト
WO2018227065A1 (en) * 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
EP3634956B1 (en) 2017-06-09 2021-04-07 Bristol-Myers Squibb Company Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
WO2019173188A1 (en) 2018-03-05 2019-09-12 Arcus Biosciences, Inc. Arginase inhibitors
WO2019173182A1 (en) 2018-03-05 2019-09-12 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
CN113166134B (zh) 2018-11-26 2024-06-14 百时美施贵宝公司 作为甲酰肽2受体激动剂的吡咯烷酮衍生物
JP7494224B2 (ja) * 2019-06-18 2024-06-03 ブリストル－マイヤーズ スクイブ カンパニー ビアリールジアルキルホスフィンオキシドｆｐｒ２アゴニスト
ES2986512T3 (es) 2020-07-09 2024-11-11 Bristol Myers Squibb Co Agonistas del receptor 2 del péptido formil pirazolona
EP4178946A1 (en) * 2020-07-09 2023-05-17 Bristol-Myers Squibb Company Oxopyrrolidine fpr2 agonists
WO2022035923A1 (en) * 2020-08-12 2022-02-17 Bristol-Myers Squibb Company Oxopyrrolidine urea fpr2 agonists
JP7830488B2 (ja) * 2021-01-21 2026-03-16 ベイジン・ティアンタン・ホスピタル Ｆｐｒ１のモジュレーター及びそれを使用する方法
JP7717816B2 (ja) * 2021-01-21 2025-08-04 バイオフロント セラピューティクス （ベイジン） カンパニー リミテッド Ｆｐｒ１のモジュレーター及びそれを使用する方法
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
IL322597A (en) 2021-12-15 2025-10-01 Adama Agan Ltd Compounds useful for the preparation of various agrochemicals and their markers
US20250205164A1 (en) 2022-05-27 2025-06-26 Asahi Group Holdings, Ltd. Fpr2 agonist containing outer membrane vesicles derived from lactic acid bacterium
CN120112538A (zh) 2022-10-13 2025-06-06 拜耳公司 Sos1抑制剂
KR20250172674A (ko) * 2023-04-18 2025-12-09 브리스톨-마이어스 스큅 컴퍼니 피롤리디논 우레아 fpr2 효능제
WO2024220453A1 (en) * 2023-04-18 2024-10-24 Bristol-Myers Squibb Company Pyrrolidinone urea fpr2 agonists
KR20250172673A (ko) * 2023-04-18 2025-12-09 브리스톨-마이어스 스큅 컴퍼니 카르보시클릭 페닐피롤리디논 우레아 fpr2 효능제
UY41082A (es) 2024-03-28 2025-08-29 Pi Industries Ltd Compuestos bicíclicos condensados y su uso como agentes de control de plagas

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063113A2 (en) 2004-12-07 2006-06-15 Portola Pharmaceuticals, Inc. Ureas as factor xa inhibitors
JP2007502843A (ja) 2003-08-21 2007-02-15 ブリストル−マイヤーズ　スクイブ　カンパニー ケモカインレセプター活性のモジュレータとしての環状誘導体
JP2014533282A (ja) 2011-11-10 2014-12-11 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体調節因子としての２，５−ジオキソイミダゾリジン−１−イル−３−フェニル尿素誘導体
WO2015079692A1 (ja) 2013-11-28 2015-06-04 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
JP2018521005A (ja) 2015-05-27 2018-08-02 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
JP2018536687A (ja) 2015-12-10 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202344A (en) 1990-12-11 1993-04-13 G. D. Searle & Co. N-substituted lactams useful as cholecystokinin antagonists
HUT75808A (en) 1994-06-02 1997-05-28 Zeneca Ltd Substituted pyrrolidones, thiazolidones and oxazolidones as herbicides and process for their preparation
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
TWI354664B (en) * 2003-08-21 2011-12-21 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine rece
WO2005047899A2 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
WO2006063293A2 (en) 2004-12-07 2006-06-15 Portola Pharmaceuticals, Inc. THIOUREAS AS FACTOR Xa INHIBITORS
US20070123508A1 (en) 2005-05-27 2007-05-31 Roger Olsson PAR2-modulating compounds and their use
EP1896461A2 (en) 2005-06-30 2008-03-12 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
BRPI0821115A8 (pt) 2007-12-18 2017-12-26 Actelion Pharmaceuticals Ltd Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
USRE49686E1 (en) 2008-09-19 2023-10-10 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
WO2010094678A1 (en) 2009-02-23 2010-08-26 F. Hoffmann-La Roche Ag Novel ortho-aminoamides for the treatment of cancer
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
CA2760887A1 (en) 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists
EP2585054A1 (en) 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
WO2012066488A2 (en) 2010-11-17 2012-05-24 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
AU2011336973A1 (en) 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
EP2648724B1 (en) 2010-12-07 2016-09-21 Actelion Pharmaceuticals Ltd. Hydroxylated aminotriazole derivatives as alx receptor agonists
PL2649068T3 (pl) 2010-12-07 2015-03-31 Idorsia Pharmaceuticals Ltd Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX
WO2012109544A1 (en) 2011-02-11 2012-08-16 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
NZ618795A (en) 2011-05-13 2015-07-31 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
HUE040145T2 (hu) 2011-10-26 2019-02-28 Allergan Inc N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
SG11201406629VA (en) 2012-04-16 2014-11-27 Allergan Inc (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
ME02990B (me) 2012-11-13 2018-10-20 Array Biopharma Inc Jedinjenja n-pirolidinil, n'-pirazolil- uree, tiouree, guanidina i cijanoguanidina kао inhibitori trka kinaze
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
KR102313757B1 (ko) 2013-07-16 2021-10-18 알러간, 인코포레이티드 펩타이드 수용체 조절제로서의 n-우레아 치환된 아미노산의 유도체
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
AU2014357342B2 (en) 2013-12-03 2019-01-17 Fmc Corporation Pyrrolidinones as herbicides
CN106459013B (zh) 2014-05-15 2019-10-25 阵列生物制药公司 作为trka激酶抑制剂的化合物及其用途
EP3247692B1 (en) 2015-01-23 2022-09-07 GVK Biosciences Private Limited Inhibitors of trka kinase
WO2016189877A1 (en) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
KR20180081528A (ko) 2015-11-24 2018-07-16 브리스톨-마이어스 스큅 컴퍼니 심장 질환의 치료를 위한 포르밀-펩타이드 수용체 2/리폭신 a4 수용체 (fpr2/alx) 타겟팅
CA3026983A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
EP3634956B1 (en) 2017-06-09 2021-04-07 Bristol-Myers Squibb Company Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615095B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
JP7094989B2 (ja) 2017-06-09 2022-07-04 ブリストル－マイヤーズ スクイブ カンパニー シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト
WO2018227065A1 (en) 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
WO2019173182A1 (en) 2018-03-05 2019-09-12 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502843A (ja) 2003-08-21 2007-02-15 ブリストル−マイヤーズ　スクイブ　カンパニー ケモカインレセプター活性のモジュレータとしての環状誘導体
WO2006063113A2 (en) 2004-12-07 2006-06-15 Portola Pharmaceuticals, Inc. Ureas as factor xa inhibitors
JP2014533282A (ja) 2011-11-10 2014-12-11 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体調節因子としての２，５−ジオキソイミダゾリジン−１−イル−３−フェニル尿素誘導体
WO2015079692A1 (ja) 2013-11-28 2015-06-04 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
JP2018521005A (ja) 2015-05-27 2018-08-02 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
JP2018536687A (ja) 2015-12-10 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト

Also Published As

Publication number Publication date
IL277044B1 (en) 2023-06-01
HUE058044T2 (hu) 2022-06-28
IL277044B2 (en) 2023-10-01
CY1124985T1 (el) 2023-01-05
US20190270704A1 (en) 2019-09-05
EP3762380A1 (en) 2021-01-13
BR112020017744A2 (pt) 2020-12-22
US11708327B2 (en) 2023-07-25
CN111868052A (zh) 2020-10-30
US11117861B2 (en) 2021-09-14
SG11202008504SA (en) 2020-10-29
PE20210046A1 (es) 2021-01-08
KR102803660B1 (ko) 2025-05-02
TWI804585B (zh) 2023-06-11
SI3762380T1 (sl) 2022-09-30
CL2020002224A1 (es) 2020-11-20
ZA202006115B (en) 2022-06-29
LT3762380T (lt) 2022-02-25
DK3762380T3 (da) 2022-01-17
US10676431B2 (en) 2020-06-09
WO2019173182A1 (en) 2019-09-12
JP2021516240A (ja) 2021-07-01
HRP20220118T1 (hr) 2022-04-15
TW202000645A (zh) 2020-01-01
AU2019232704B2 (en) 2024-03-21
AU2019232704A1 (en) 2020-10-22
PT3762380T (pt) 2022-01-25
EP3981767A1 (en) 2022-04-13
MY204384A (en) 2024-08-27
PL3762380T3 (pl) 2022-02-21
KR20200128709A (ko) 2020-11-16
ES3061495T3 (en) 2026-04-06
US20210371378A1 (en) 2021-12-02
IL277044A (en) 2020-10-29
EP3762380B1 (en) 2021-12-15
ES2904483T3 (es) 2022-04-05
US20200255375A1 (en) 2020-08-13
AR114429A1 (es) 2020-09-02
CN111868052B (zh) 2024-03-08
EA202092094A1 (ru) 2020-12-10
CA3092927A1 (en) 2019-09-12
RS62833B1 (sr) 2022-02-28
SMT202200067T1 (it) 2022-03-21
EP3981767B1 (en) 2025-12-31
MX2020009000A (es) 2020-10-05

Similar Documents

Publication Publication Date Title
KR102803660B1 (ko) 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제
KR102623473B1 (ko) 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
KR102772801B1 (ko) 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
EP3986903B1 (en) Biaryl dialkyl phosphine oxide fpr2 agonists
JP2023533039A (ja) ピラゾロンホルミルペプチド２受容体アゴニスト
KR20230051525A (ko) 옥소피롤리딘 우레아 fpr2 효능제
HK40071411A (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
US20230348426A1 (en) Oxopyrrolidine fpr2 agonists
HK40035056A (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
HK40035056B (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
EA043110B1 (ru) Фенилпирролидиноновые агонисты формилпептидного рецептора 2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220419

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220530

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220906

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221005

R150 Certificate of patent or registration of utility model

Ref document number: 7155276

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250